Clostridioides Difficile Market Research
What is Clostridioides Difficile?
Clostridioides difficile (C. diff) is an infection that affects the large intestine. The C. diff bacteria infects the colon, causing inflammation. In some individuals, C diff. develops after taking antibiotics for other infections, as antibiotics can disrupt the healthy bacteria in the intestines. In these cases, symptoms of C diff. may begin to develop 5-10 days after starting the antibiotics course. Symptoms of C diff. include: diarrhea, moderate to severe abdominal cramping, fever, dehydration, loss of appetite, weight loss, swollen abdomen and blood in stool. In some patients, C. diff may be recurrent, resulting in another infection in the following 2-8 weeks. Antibiotics are typically used for treating C. diff, but in patients with recurrent infections, treatments including surgery and fecal microbiota transplantation (FMT) may be utilized.
Spherix Global Insights – Gastroenterology – Clostridioides Difficile
Spherix Global Insights’ gastroenterology therapeutic team is a leading provider of independent syndicated clostridioides difficile market research, insights, business intelligence & advisory services.
Spherix’s gastroenterology team publishes four (4) studies in C. diff including:
- Market Dynamix™: Clostridioides Difficile (US)
- Launch Dynamix™: Rebyota (Ferring/Rebiotix) in Clostridium Difficile Infection (US)*
- Launch Dynamix™: Ridinilazole (Summit) in Clostridium Difficile Infection (US)*
- Launch Dynamix™: SER-109 (Seres) in Clostridium Difficile Infection (US)*
*Pending approvals and launch
Spherix’s Market Dynamix™ service includes analysis of markets anticipated to experience a paradigm shift within the next three to five years. Its insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.
Spherix’s Launch Dynamix™ service consists of two parts: monthly KPI tracking and quarterly deep dives. Monthly KPIs provide monthly benchmarking of newly launched products for the first eighteen months of commercial availability, and quarterly deep dive reports covering promotional activity, barriers to uptake, and patient types being identified for the launch brand.
Follow Spherix Gastroenterology on Social Media
Follow us for gastroenterology industry news, insights & analysis:
For Guests & Current Clients
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: